Results 241 to 250 of about 75,185 (305)

L-DOPA Test in the Diagnosis of Childhood Short Stature: Evaluation of Growth Hormone Peaks Over Time. [PDF]

Endocrinol Diabetes Metab
Castelli B, De Santis R, Carrera S, Malanima MA, De Masi S, Stagi S.   +5 more
europepmc   +1 more source

Intrastriatal injection of alpha-synuclein preformed fibrils to rats results in L-DOPA reversible sensorimotor impairments and alterations in non-motor function. [PDF]

Front Neurosci
Fleming SM, Scott S, Hamad EJ, Herman DE, Holden JG, Yan L, Linning-Duffy K, Kemp CJ, Patterson JR, Miller KM, Kubik M, Kuhn N, Stoll AC, Duffy MF, Steece-Collier K, Cole-Strauss A, Lipton JW, Luk KC, Sortwell CE.   +18 more
europepmc   +1 more source

Enhancement of Haloperidol-Induced Catalepsy by GPR143, an l-DOPA Receptor, in Striatal Cholinergic Interneurons. [PDF]

J Neurosci
Hatzipantelis CJ.
europepmc   +1 more source

Reduced striatal M4-cholinergic signaling following dopamine loss contributes to parkinsonian and l-DOPA-induced dyskinetic behaviors. [PDF]

Sci Adv
Nielsen BE, Ford CP.
europepmc   +1 more source

Effects of genetic knockdown of the serotonin transporter on established L-DOPA-induced dyskinesia and gene expression in hemiparkinsonian rats. [PDF]

Neuropharmacology
McManus G, Galfano A, Budrow C, Lipari N, Tseng KY, Manfredsson FP, Bishop C.   +6 more
europepmc   +1 more source

Sustained effects of repeated levodopa (L-DOPA) administration on reward circuitry, effort-based motivation, and anhedonia in depressed patients with higher inflammation. [PDF]

Brain Behav Immun
Bekhbat M, Li Z, Dunlop BW, Treadway MT, Mehta ND, Revill KP, Lucido MJ, Hong C, Ashchi A, Wommack EC, Goldsmith DR, Haroon E, Miller AH, Felger JC.   +13 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

L-DOPA IN IDIOPATHIC PARKINSONISM

Lancet, The, 1969
Abstract Twenty-six patients with idiopathic parkinsonism were admitted to a " double blind " " within-patient " comparison between oral L-dopa and placebo. Twenty patients completed the programme. The intake of L-dopa was gradually increased to maximum tolerated dosage (1-8 g.
D B, Calne, G M, Stern, A S, Spiers, D R, Laurence   +3 more
exaly   +3 more sources

L-Dopa and Oligozoospermia

Andrologia, 2009
A clinical investigation of L-Dopa on idiopathic oligozoospermia is carried out. Thirty nine male oligozoospermic patients with primary sterility were divided in two groups. The first group of 25 patients was treated with 500 mg a day during two months. The second group of 14 patients received 750 mg a day for the same time.
J C, Lavieri, A A, Pierini
openaire   +2 more sources

L-Dopa and Parkinsonism

Nature, 1970
This new treatment for an old disease has its origins in pharmacological research of the late 1950s. There is still not full agreement about how L-dopa functions in the nervous system, but, as this review shows, there is ample evidence to support the clinical work in progress since 1961.
D B, Calne, M, Sandler
openaire   +2 more sources

L‐Dopa‐Induced Asterixis

Psychiatry and Clinical Neurosciences, 1985
Abstract: Three cases with the occurrence of asterixis during the administration of L‐dopa were reported. Liver and metabolic functions were normal in all the patients. Upon the appearance of asterixis no other involuntary movements probably resulting from an excess administration of L‐dopa were observed.
I, Kobayashi, M, Osawa, K, Ohta, S, Maruyama   +3 more
openaire   +2 more sources